The eGFR-C study: accuracy of glomerular filtration rate (GFR) estimation using creatinine and cystatin C and albuminuria for monitoring disease progression in patients with stage 3 chronic kidney disease - prospective longitudinal study in a multiethnic population by Lamb, EJ et al.
Lamb et al. BMC Nephrology 2014, 15:13
http://www.biomedcentral.com/1471-2369/15/13STUDY PROTOCOL Open AccessThe eGFR-C study: accuracy of glomerular filtration
rate (GFR) estimation using creatinine and cystatin
C and albuminuria for monitoring disease
progression in patients with stage 3 chronic kidney
disease - prospective longitudinal study in a
multiethnic population
Edmund J Lamb1*, Elizabeth A Brettell2, Paul Cockwell3, Neil Dalton4, Jon J Deeks2,5, Kevin Harris6, Tracy Higgins7,
Philip A Kalra8, Kamlesh Khunti9, Fiona Loud10, Ryan S Ottridge2, Claire C Sharpe12, Alice J Sitch5, Paul E Stevens11,
Andrew J Sutton13, Maarten W Taal14 and on behalf of the eGFR-C study groupAbstract
Background: Uncertainty exists regarding the optimal method to estimate glomerular filtration rate (GFR) for disease
detection and monitoring. Widely used GFR estimates have not been validated in British ethnic minority populations.
Methods/design: Iohexol measured GFR will be the reference against which each estimating equation will be
compared. The estimating equations will be based upon serum creatinine and/or cystatin C. The eGFR-C study has 5
components:
1) A prospective longitudinal cohort study of 1300 adults with stage 3 chronic kidney disease followed for 3 years
with reference (measured) GFR and test (estimated GFR [eGFR] and urinary albumin-to-creatinine ratio) measurements
at baseline and 3 years. Test measurements will also be undertaken every 6 months. The study population will
include a representative sample of South-Asians and African-Caribbeans. People with diabetes and proteinuria
(ACR ≥30 mg/mmol) will comprise 20-30% of the study cohort.
2) A sub-study of patterns of disease progression of 375 people (125 each of Caucasian, Asian and African-Caribbean
origin; in each case containing subjects at high and low risk of renal progression). Additional reference GFR
measurements will be undertaken after 1 and 2 years to enable a model of disease progression and error to be built.
3) A biological variability study to establish reference change values for reference and test measures.
4) A modelling study of the performance of monitoring strategies on detecting progression, utilising estimates of
accuracy, patterns of disease progression and estimates of measurement error from studies 1), 2) and 3).
5) A comprehensive cost database for each diagnostic approach will be developed to enable cost-effectiveness
modelling of the optimal strategy.
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The performance of the estimating equations will be evaluated by assessing bias, precision and accuracy. Data will be
modelled as a linear function of time utilising all available (maximum 7) time points compared with the difference
between baseline and final reference values. The percentage of participants demonstrating large error with the
respective estimating equations will be compared. Predictive value of GFR estimates and albumin-to-creatinine ratio will
be compared amongst subjects that do or do not show progressive kidney function decline.
Discussion: The eGFR-C study will provide evidence to inform the optimal GFR estimate to be used in clinical practice.
Trial registration: ISRCTN42955626.
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Chronic kidney disease (CKD) is prevalent in the general
population [1-4] and is commonly identified using estima-
tion of glomerular filtration rate (GFR) or detection of pro-
tein in urine (albuminuria/proteinuria). GFR is accepted as
the best overall measure of kidney function and is central
to diagnosis, staging and management of CKD. Ideally GFR
would be measured using reference procedures which fol-
low the clearance of an infused exogenous substance (e.g.
inulin, 125I-iothalamate or iohexol [5]). However, these
methods are cumbersome and impractical for general kid-
ney disease detection and management. Estimation of GFR
(estimated GFR [eGFR]) using equations based on serum
creatinine with adjustments for age, gender and race are
widely used as surrogate measures of GFR. In England, the
National Institute for Health and Care Excellence (NICE)
have recommended which people should be tested for the
presence of CKD (e.g. those with diabetes or hypertension)
and that GFR should be estimated 6-monthly in people
with stage 3 CKD (GFR 30–59 mL/min/1.73 m2) [6], com-
prising approximately 6-7% of the overall UK population
[3,7]. The aim of disease detection is to identify and manage
those most likely to progress to kidney failure and/or those
at high risk of morbidity and mortality. In addition to the
accurate identification of CKD, the ability of tests to identify
which individuals with CKD will have high risk (i.e. pro-
gressive or mortal) disease is a crucial issue. Many people
with stage 3 CKD are not at increased risk of progressive
disease and there are concerns that CKD detection using
creatinine-based approaches may be identifying individuals
who are at low risk and unlikely to benefit from active man-
agement and inappropriate surveillance [8]. Recently, newer
equations utilising cystatin C instead of, or in addition to,
creatinine have been proposed. Given the high costs of
cystatin C testing compared with creatinine, it is critical
that its diagnostic accuracy and prognostic ability are care-
fully validated ahead of widespread introduction into the
National Health Service.
Measuring GFR
Standard clearance of inulin, including urine collection,
remains the ‘gold-standard’ method for GFR measurementbut few studies use this. Most evaluations of GFR equa-
tions have used radiolabelled plasma clearance methods
which are assumed to be closely related to inulin clear-
ance. Radiolabelled iothalamate plasma clearance was the
method used for developing the Modification of Diet in
Renal Disease (MDRD) Study [9] and Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) [10] GFR-
estimating equations (see below), whilst the CKD-EPI
equation validation dataset also used a variety of other
reference GFR methods including iohexol [10]. Although
regarded as the reference approach to assessment of kid-
ney function, it is increasingly appreciated that non-inulin
plasma clearance methods are not all equivalent [11]. Fur-
thermore, as with any physiological measurement, GFR
has an intrinsic biological variability, the understanding of
which is critical to appreciation of disease-related change.
Using a variety of reference markers, values (coefficient of
variation, CV%) ranging between 5.5% and 11.6% have
been reported for the biological variation of GFR [12-18].
However, most of these estimates were not derived using
classical biological variation studies [19].
Estimating GFR
Use of the MDRD Study equation (MDRD) [9,20,21], which
estimates GFR adjusted for body surface area (BSA), has
been endorsed by national professional healthcare organisa-
tions [6,22]. However, accuracy of the equation is sub-
optimal. In the CKD field, accuracy of GFR estimating
equations is commonly expressed as the P30, the percentage
of eGFR values within 30% of ‘true’ GFR. This metric cap-
tures aspects of both imprecision (measurement error) and
bias (systematic over- and/or under-estimation). Reported
P30 values for the MDRD equation typically range between
73% to 93% [23]. The MDRD equation has also been cri-
ticised on the basis that it significantly underestimates
GFR (particularly in individuals with GFR greater than
60 mL/min/1.73 m2) and has poor precision [10].
A revised equation, the Chronic Kidney Disease Epi-
demiology Collaboration (CKD-EPIcreatinine) produces less
biased estimates of GFR at higher levels of kidney function
[10], although reportedly less accurate estimates as GFR
falls below 60 mL/min/1.73 m2 [23]. P30 values for the
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the MDRD equation in studies that have undertaken a
head-to-head comparison [23]. Cystatin C has been pro-
posed as an improved marker of GFR compared with cre-
atinine [24,25]. Recently, the CKD-EPI Collaboration have
published two further CKD-EPI equations; one based on
cystatin C (CKD-EPIcystatin C) and one using both cystatin
C and creatinine (CKD-EPIcystatin and creatinine C) [26]. In
the external validation datasets of Inker et al. [26] the
CKD-EPIcystatin C and CKD-EPIcystatin and creatinine C equa-
tions achieved P30 values of 86% and 92% respectively.
There has been little independent validation to date of
these latter equations [27,28]. Amongst older people the
MDRD equation achieved a P30 of 81% compared with
86% for the CKD-EPIcystatin and creatinine C equation [27].
Estimating GFR in British ethnic minority populations
People from South Asian and African-Caribbean back-
grounds are at 3 to 5-fold increased risk of developing
established renal failure compared with Caucasians. Whilst
GFR-estimating equations have been validated in African-
Caribbean communities from North America [29] and en-
demic Asian populations [30-35] there is no independent
validation in British African-Caribbean populations; and
no data at all amongst people originating from India,
Pakistan, Sri Lanka and Bangladesh). There is some
evidence that the black ethnicity coefficients in GFR es-
timating equations developed for use amongst African-
Americans may not be transferable to other populations
of African ancestry [36,37].
Progression of kidney disease
There is no consistent definition of what constitutes renal
progression in the literature. Many studies have used a
doubling of serum creatinine, corresponding to an ap-
proximate halving of GFR, as an end-point defining pro-
gression, but this is insufficiently sensitive to be useful in
clinical practice. Kidney Disease Improving Global Out-
comes (KDIGO) have defined progression as a move to a
higher disease category (e.g. stage 3A [GFR 45–59 mL/
min/1.73 m2] to stage 3B [GFR30-44 mL/min/1.73 m2])
confirmed by a fall in GFR of greater than or equal to
25%, an increase in albuminuria, a greater than 25% de-
cline in GFR (e.g. a decline from 60 mL/min/1.73 m2 to
less than 45 mL/min/1.73 m2) or a greater than 10%/year
decline in GFR (e.g. a decline from 60 mL/min/1.73 m2 to
less than 54 mL/min/1.73 m2 in one year) [38]. NICE de-
fined progression as a decline in GFR of more than 5 mL/
min/1.73 m2/year, or more than 10 mL/min/1.73 m2 aver-
aged over 5 years [6].
Progression is not necessarily common even amongst
people with known CKD e.g. amongst people with stage
3 CKD only 1.3% progressed to stage 5 CKD (established
renal failure, typically requiring dialysis or transplantation)over 5 years [39]. Amongst community dwelling older
(greater than 65 years) adults with stage 3 CKD mean GFR
declines of 3.6 mL/min/1.73 m2/year and 2.8 mL/min/
1.73 m2/year have been reported respectively in male and
female subjects with diabetes and somewhat lower values
amongst subjects without diabetes (1.9 mL/min/1.73 m2/
year and 1.1 mL/min/1.73 m2/year amongst males and
females respectively) [40]. In the REIN study proteinuric
(greater than 1 g/24 h) non-diabetic subjects with GFRs in
the approximate range 30–50 mL/min/1.73 m2 showed a
decline of GFR of 7.0 mL/min/1.73 m2/year with slightly
lower values being observed in those receiving renin-
angiotensin-aldosterone system (RAAS) blockade [41].
There are some data, mainly restricted to small studies
in people with diabetes, describing disease progression in
terms of decline in reference GFR measurements [42,43].
Generally, disease progression in people with diabetes has
been described as following a broadly linear decline, being
influenced by blood pressure and albuminuria and amelio-
rated by antihypertensive medication/RAAS blockade
[42,44,45]. A similar pattern has been observed using esti-
mated rather than measured GFR [46].
Identifying progressive kidney disease
A significant problem is the ability of GFR-estimating
equations to identify progression of kidney disease against
background change in GFR (i.e. that due to ‘normal’ age-
ing; commonly cited as approximately minus 1 mL/min/
1.73 m2/year) given the biological and measurement vari-
ability of both reference and estimated GFR. The intrain-
dividual variation (CVI) of the main determinant (serum
creatinine) of eGFR has been reported as 4.3% [47] to
which should be added intralaboratory imprecision (CVA)
of approximately 3.0% [22]. On this basis, the critical dif-
ference or reference change value (RCV) for serum cre-
atinine is 13% (i.e. this is the difference that can be
considered ‘real’ with 95% probability). The power func-
tion in the MDRD equation (−1.154, Table 1) increases
the impact of CVI to an average of 5.4%. Consequently the
RCV for eGFR derived using the MDRD equation be-
comes 14.4%. As an example of this, in an individual a
GFR of 60 mL/min/1.73 m2 will need to fall below 51 mL/
min/1.73 m2 before it can be confidently considered a sig-
nificant decrease. Some [48,49], although not the majority
[50-53] of data suggests that the biological variation of
serum cystatin C is greater than that of creatinine. If this
were the case then it would clearly impact on the ability of
cystatin C based GFR-estimating equations to detect
changes in true GFR vis-à-vis serum creatinine.
GFR changes of this order exceed the limit that most ne-
phrologists would consider a clinically insignificant change.
However, there are no prospective longitudinal data asses-
sing the relative abilities of GFR-estimating equations to
detect change in underlying measured GFR. One recent
Table 1 Equations to be used to estimate glomerular filtration rate (GFR)
Abbreviation GFR equation expressed as a single equation
MDRD [20] 175 × Scr -1.154 × age-0.203 × 0.742 [if female] × 1.212 [if black]
CKD-EPIcreatinine [10] 141 x min(Scr/κ, 1)
α × max(Scr/κ, 1)-1.209 × 0.993Age × 1.018 [if female] × 1.159 [if black], where κ is 0.7 for females and 0.9
for males, α is −0.329 for females and −0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the
maximum of Scr/κ or 1
CKD-EPIcystatin C [26] 133 × min(Scys/0.8, 1)
-0.499 × max(Scys/0.8, 1)-1.328 × 0.996Age × 0.932 [if female] where min indicates the minimum of Scr/κ
or 1, and max indicates the maximum of Scr/κ or 1.
CKD-EPIcystatin-creatinine [26] 135 × min(Scr/κ, 1)
α × max(Scr/κ, 1)-0.601 × min(Scys/0.8, 1)-0.375 × max(Scys/0.8, 1)-0.711 × 0.995Age × 0.969 [if female] × 1.08
[if black] where κ is 0.7 for females and 0.9 for males, α is −0.248 for females and −0.207 for males, min indicates the
minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1.
Abbreviations: CKD-EPI Chronic Kidney Disease Epidemiology Collaboration, MDRD Modification of Diet in Renal Disease, Scr serum creatinine, Scys serum cystatin C.
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tions compared with 125I-iothalamate measured GFR over
time in people with kidney disease [54]. The authors con-
cluded that GFR estimating equations accurately reflected
changes in measured GFR over time. The study was robust
(3,532 participants with CKD followed for a mean of
2.6 years) but retrospective in nature, and did not include
data derived using cystatin C [54]. Observational data
suggests that for identification of progressive CKD the
combination of eGFR using cystatin C and albumin-to-
creatinine ratio (ACR) ranks highest, followed by eGFR
using cystatin C alone, then the combination of ACR
and eGFR using creatinine, and finally eGFR using cre-
atinine alone [55].
Objectives of the eGFR-C study
Whilst there is a significant literature describing the accur-
acy of creatinine-based eGFR against reference methods,
there are no studies addressing the ability of GFR estimat-
ing equations, including those incorporating cystatin C, to
detect change in GFR. Furthermore, there are no data ad-
dressing the accuracy of these equations in black and mi-
nority ethnic populations. The eGFR-C study will evaluate
the performance of GFR-estimating equations, including
novel equations incorporating cystatin C, in assessing and
monitoring measured GFR in people with stage 3 CKD.
The data will be analysed to assess the impact of ethnicity,
proteinuria and diabetes on equation performance. eGFR-
C will assess whether eGFR using either creatinine or
cystatin C or a combination of both is superior at detecting
changes in GFR as measured by a reference GFR method.
The utility of baseline eGFR and urinary ACR to predict
which people are likely to show progressive kidney disease
will also be tested. A simple economic evaluation of the
relative costs of the diagnostic tests will be included to en-
able cost-effectiveness modelling.
Methods/design
eGFR-C is a study which will provide the required evi-
dence to identify the optimal estimate of GFR to use in
clinical practice (Figure 1).There are five components to the study:
1) A 3-year prospective longitudinal cohort study using
6-monthly estimates of GFR and baseline and final
reference GFR values to assess and compare the
accuracy and precision of each estimate of GFR and
change in GFR. This will include assessments in high
risk subgroups and ethnic groups.
2) Investigation and modelling of patterns of
progression of GFR in a subset of the cohort,
stratified by ethnicity, presence of diabetes and
proteinuria, who will receive annual reference GFR,
assessing risk factors and over time.
3) A sub-study investigating sources of variability to
estimate the components of measurement error in
each measure and estimate of GFR.
4) Using information from 1), 2) and 3) modelling of
alternative monitoring strategies, using different
estimates of eGFR and monitoring frequencies.
5) A model-based cost-effectiveness analysis.
Prospective longitudinal cohort study
The primary study will comprise a prospective longitu-
dinal cohort study in which adults (n = 1300) with stage
3 CKD, enriched to include people more likely to have
progressive kidney disease (i.e. those with proteinuria
and/or diabetes), will be recruited from six UK centres.
Participants will be recruited from both primary (two cen-
tres) and secondary/tertiary (four centres) care. People
aged 18 years and older having stage 3 CKD (eGFR mea-
surements between 30 and 59 mL/min/1.73 m2 inclusive
sustained over at least 3 months prior to recruitment) will
be included. Recruitment will be targeted such that 20% to
30% of recruits will have proteinuria (ACR ≥30 mg/mmol)
and a similar proportion will have diabetes. The prevalence
of proteinuria and diabetes will be monitored during the
course of the study to ensure reasonable representation.
Participants will attend hospital in the morning having
been advised to consume a light breakfast (no meat or
fish). A clinical (including cardiovascular) and drug his-
tory will be recorded using a standardised questionnaire.
Figure 1 General study schema.
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version of the 2011 UK Census Questionnaire. Height will
be measured to the nearest 0.1 cm with a rigid stadi-
ometer. Body weight will be measured in light indoor
clothing to the nearest 0.1 kg. Waist circumference will be
recorded to the nearest 0.1 cm at the mid-point between
the lower costal margin and the level of the anterior su-
perior iliac crest. Hip circumference will be measured at
the widest point of the hips and the maximal protrusion
of the gluteal muscles. Brachial blood pressure will be
measured three times in the sitting position as recom-
mended [56]. Blood will be taken for serum creatinine,
cystatin C and a urine sample will be collected for ACR.
Further aliquots of serum, plasma and urine will be
stored for potential analysis of future markers of GFR.
An iohexol reference GFR measurement will be under-
taken in addition to estimation of GFR using four GFR es-
timating equations (MDRD, CKD-EPIcreatinine, CKD-
EPIcystatin, and CKD-EPIcystatin-creatinine) (Table 1).
Participants will be followed for three years. All the
above measurements and the clinical questionnaire will
be repeated at 36 months. At each 6 month interval, all
participants will have blood taken for serum creatinine,
cystatin C and a urine sample will be collected for ACR.
GFR will be estimated as above.
Participants will be excluded if they are pregnant, have
a history of untoward reactions to iodinated contrast
media, have life expectancy which makes study comple-
tion unlikely [57], are unable to consent due to cognitive
impairment, are whole- or part-limb amputees, have a
recent (last 6 months) episode of acute kidney injury (as
defined by the Acute kidney Injury Network criteria [58])
or have sickle cell disease.GFR will be measured using an iohexol clearance
method. A 5 mL bolus of Omnipaque 240 (518 g/L iohexol
corresponding to 240 g/L of iodine, GE Healthcare www.
gelifesciences.com) followed by 10 mL of normal saline will
be injected into the antecubital vein. Blood samples will be
collected at 5, 120, 180 and 240 minutes after injection.
Samples will be stored at −80°C prior to analysis. Iohexol
will be determined using isotope dilution mass spectrom-
etry (ID-MS) [59] and GFR calculated [60]. Serum and
urinary creatinine will be measured using ID-MS and en-
zymatic assays respectively, both traceable to a reference
methodology. Serum cystatin C will be measured using a
nephelometric immunoassay with calibration traceable to
the international certified reference material ERM-DA471/
IFCC [61]. Urinary albumin will be measured using a
nephelometric immunoassay.
Blood samples will be collected using standard vene-
puncture and phlebotomy procedures and samples will
be transported to the local laboratory, where plasma/serum
will be separated within 4 h of venepuncture. Aliquots of
serum/plasma and urine will then be stored at −80°C pend-
ing transportation to the central laboratories and analysis.
Clinicians and others involved in patient care will be
blinded to the specific study measurements (reference
[iohexol] GFR, estimated GFR and ACR) for the duration
of the study.
Sub-study of patterns of disease progression
At three centres 125 each of Caucasian, African-Caribbean
and Asian subjects (i.e. n = 375 in total), stratified in each
group by higher and lower risk of disease progression
(approximately 60 with diabetes and/or proteinuria and
60 with neither diabetes nor proteinuria) will undergo
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period. At each point indicated subjects will undergo a
reference GFR measurement in addition to cystatin C
and creatinine eGFRs and ACR. The study will enable a
model of disease progression to be developed based on
reference GFR measurement enabling optimal monitor-
ing frequencies in a high-risk cohort to be defined. This
number of subjects should provide a range of values
over the main factors considered to influence disease
progression and allow assessment of covariates in the
statistical model. Further assessment of covariates will
be performed by combining the data from this sub-
study with the main study. Inclusions/exclusions and la-
boratory methods for this sub-study will be as above.
Study of intra-individual biological variability
A study will be undertaken to define the normal bio-
logical variability of a reference GFR test in addition to
the eGFR tests. Twenty people with stage 3 CKD will
undergo four iohexol reference measures of GFR in four
successive weeks, with standardisation for time of day
(morning after a light breakfast) and day of week. Inclu-
sions/exclusions and laboratory methods for this sub-
study will be as above.
Sample size calculations
1) Prospective longitudinal cohort study
The sample size calculation for the main study
focuses on the ability to detect differences in
accuracy of measurement between the
MDRDcreatinine equation and the CKD-EPIcystatin C
equation. We will also make secondary comparisons
with the other equations. The measure of accuracy
we will use is the P30. Sample size is based on a
simulation study to estimate differences in P30 and
estimates of rate of change which are not amenable
to algebraic solution. Our simulation
modelled the full structure of the study including
random variability, and computed statistical power
through noting the percentage of simulations
yielding statistically significant results (P < 0.05) for
analysis of each outcome. Power estimates are based
on 1000 simulations.
With 1000 evaluable subjects our simulations
showed the study to have 87% power at the 5%
significance level to detect a difference of 5% in P30,
between 81% and 86%, which is of a magnitude
considered clinically important and likely to occur
with the expected scale of differences in imprecision
between the equations [27]. We thus aim to recruit
1300 people, which allowing for 15-20% drop-out
will deliver over 90% power. The proposed sample
size in the ethnicity subgroups will allow P30 estimatesto be reported with 95% confidence intervals of 10
percentage points wide.
Rates of change in estimated and measured GFR will
be obtained by linear regression. Padala et al.
proposed two cut-points for estimating accuracy of
rates of change: greater than 3 mL/min/1.73 m2/year
error and greater than 5% error [54]. The study will
have over 90% power and over 80% power at the 5%
significance level to detect differences in these two
outcomes respectively, for differences of a magnitude
corresponding with P30 measures of 81% and 86%.
2) Sub-study of patterns of disease progression
A sample size of 375 was chosen based on practical
considerations to allow investigation of twelve
covariates of interest (gender, age, diabetes, duration
of diabetes, ethnicity, albuminuria, baseline GFR,
blood pressure, body mass index, waist
circumference, smoking status and presence of
vascular disease) in addition to variables for time,
drug effects and random effects. Another
consideration was to include a reasonable number of
subjects in each of the ethnic groups and high and
low risk subgroups to estimate disease progression.
3) Study of intra-individual biological variation
The biological variation of GFR has been estimated
at approximately 10% (see above). On this
assumption, the sample size (n = 20) and number of
repeat samplings proposed will enable the CVI to be
estimated within ±2% of its true value.
Study steering committee
The study steering committee comprises an independent
chairperson (a consultant nephrologist), a second inde-
pendent consultant nephrologist, a patient advocate, the
study statistician, an independent statistician, the chief
investigator, the study lead research nurse and one other
co-investigator.
Data analysis
Prospective longitudinal cohort study
Data will be analysed to address three main questions:
1. Which of the GFR-estimating equations is the most
accurate assessment of reference GFR?
2. Which GFR-estimating equation most accurately
reflects change in GFR?
3. Which GFR-estimating equation, together with
ACR, or ACR alone, most accurately predicts those
people that have progressive loss of kidney function
(CKD progression)?
In each case, data will be further analysed to assess
whether observed relationships amongst African-Caribbean
and South-Asian subjects differ from those observed
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are predictors.
1. Which of the GFR-estimating equations is the most
accurate assessment of reference GFR?
Accuracy will be assessed by establishing the propor-
tion of GFR estimates within 30% (P30) of iohexol GFR,
using baseline measures. P30 values will be compared be-
tween GFR estimating equations using McNemar’s test
for paired data. Additional analysis will consider the
mean and median, interquartile range and root mean
square error of the distribution of differences.
2. Which GFR-estimating equation most accurately reflects
change in GFR?
Rate of change in eGFR will be established by linear
regression [54] utilising all available (maximum 7) eGFR
time points, and will be compared with the difference
between final and baseline reference GFR values. Differ-
ences in large error rates (greater than 3 mL/min/
1.73 m2/year, or greater than 5%/year difference in slope)
will be compared using McNemar’s test. Additional
analyses will consider the predictive ability of the tests
to detect i) a change in iohexol GFR of greater than
25%; ii) a decline in GFR of greater than or equal to 10
mL/min/1.73 m2 over the three years; and iii) a change
that exceeds the RCV derived for the reference GFR
test in the measurement variability study described
below.
3. Which GFR-estimating equation, together with
ACR, or ACR alone, most accurately predicts those
people that have progressive loss of kidney function
(CKD progression)?
Models will be constructed to predict time to progres-
sion based on baseline eGFRs and ACR. Progression
will be defined in terms of decline in reference GFR
(change in iohexol GFR > 10 mL/min/1.73 m2) or an in-
crease in albuminuria category, as suggested by KDIGO
[38]. Progression will only be detected at one of 6 time
points, hence piecewise survival models will be fitted to
determine whether the prognostic value of ACR and
the estimated GFRs is independent of other risk factors.
We will develop a prognostic model utilising age, gen-
der, ethnicity, body mass index, waist circumference,
mean arterial blood pressure, diabetes mellitus, smok-
ing status, and presence of vascular disease in addition
to baseline ACR and the various eGFRs. Both propor-
tional and non-proportional hazards will be considered.
Bootstrap validation will be used with these prediction
models.Sub-study of patterns of disease progression
How does GFR progress over time and what are the
optimal monitoring times? The rate of decline (mL/
min/1.73 m2/year) in reference GFR, and the difference
between reference GFR and estimated GFRs (referred to
as error), measured every 12 months will be modelled
over time using a longitudinal linear or nonlinear (expo-
nential decline) random coefficients regression model to
estimate average and variability in disease progression
and error. Parameters of the model for each outcome
will be estimated using maximum likelihood. Covariates
to be explored in the model will be as described above.
The effect of covariates on the population average inter-
cept and longitudinal time effect parameters will be
assessed. The method of backward elimination will be
used to remove covariates which are not significant from
the model. A linear relationship between disease pro-
gression and drug name or drug class will be explored.
Analysis will be undertaken using NONMEM version
7.1.2, R open source software and PFIM version 3.2.2
optimal design algorithms (R open source software). The
PFIM algorithms will be used to calculate the D-optimal
[62] sampling times from the disease progression model
based on reference GFR for individuals with diabetes and/
or proteinuria, and for those individuals with neither of
these conditions. Optimal monitoring strategies will be se-
lected from a set of designs and for important subgroups
of the population found to be significant in the disease
progression model. The monitoring strategies identified
will be used as the basis for further simulations.
Study of intra-individual biological variation
Pre-analytical variables will be standardised as described
above. All samples for all analytes will be assayed in dupli-
cate and the analytical variance (SDA
2 ) will be calculated
from the differences between the duplicate measurements.
The total (CVT), analytical (CVA) and within-individual
(CVI) components of variation will be calculated using
nested ANOVA [19]. The critical difference (reference
change value, RCV) for significant changes in serial results
(P less than 0.05) and the number of specimens required
to estimate the homeostatic set-point of an individual
(within ±10% with a confidence of 95%) will also be esti-
mated. The derived RCV for the reference GFR will be
used to test the ability of estimated GFR equations to de-
tect a true change in GFR (see study 1, part 2 above).
Modelling monitoring strategies
Whilst our longitudinal cohort will not have adequate
power to detect differences in progression, our estimates
of the accuracy of eGFR (study 1), patterns and determi-
nants of progression (study 2), and intra-individual bio-
logical variation (study 3) can be combined in a model
to evaluate the impact of alternative monitoring
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True GFR values will be modelled over time for repre-
sentative cohorts of people, and performance of alterna-
tive monitoring strategies in detecting progression to
stage 4 CKD (varying in timing and choice of eGFR
equation) will be simulated utilising estimates of meas-
urement error and accuracy. Outcome variables which
will be assessed will include false positive progression
rates, and the sensitivity and delays in detecting
progression.
Health economics study
The aim of the health economics evaluation is to deter-
mine the cost-effectiveness of implementing cystatin C-
based eGFR or a combination of both cystatin C and
creatinine-based eGFR in subjects that are initially stage
3 CKD compared with MDRD (creatinine-based) eGFR
alone. The cost-effectiveness analysis will take the form
of a cost-utility analysis in which the outcome measure
will be the cost per quality adjusted life year (QALY).
This will be undertaken by extending the monitoring
strategy by extrapolating the rate of change in GFR be-
yond the end of the trial through the use of secondary
data sources to link the error in estimated GFR to pa-
tient outcomes, which will include myocardial infarction,
kidney transplant, and established renal failure. It is un-
likely that differences in quality of life will be seen for
patients receiving alternative monitoring strategies dur-
ing the period of the trial, and therefore quality of life
data (e.g. EQ-5D) is not being collected during this study.
Instead secondary sources will be used to inform the im-
pact of the long term outcomes of CKD on quality of life.
Cost data collection will be undertaken prospectively
for all subjects in the cohort study in order to inform the
cost component of the cost-effectiveness analysis. The main
resource uses monitored during the trial will include the
following:
1. Diagnostic testing procedures implemented.
2. Resource uses involved in the diagnostic testing
procedures (e.g. urine ACR).
3. Other related procedures, including level of health
care professional involvement in the procedure,
equipment required, overheads, consumables etc.
The costs obtained will be dictated by the recommended
investigations and interventions by GFR category in NICE
Clinical Guideline 73 [6]. The difference in cost will be that
between GFR category and rate of change in GFR assessed
by creatinine-based estimating equations versus cystatin
C-based equations.
The model-based analysis will be carried out following
the conclusion of the data collection undertaken during
the cohort study. A decision analytic model will be usedto allow extrapolation of the cost and effectiveness pa-
rameters beyond the data observed during the trial (and
to allow extrapolation to other settings). The model will
consider the impact of the error in GFR measures on pa-
tient outcomes. The results of the economic analysis will
be presented using cost-effectiveness acceptability curves
to reflect sampling variation and uncertainties in the ap-
propriate threshold value by which the cost-effectiveness
of the different diagnostic strategies will be judged.
Discussion
CKD is common and is usually detected using estimated
GFR and/or albuminuria. Estimation of GFR on every blood
creatinine request received by laboratories has been recom-
mended by the Department of Health [63] and NICE [6]. It
is estimated that more than 50 million GFR estimates are
produced by UK NHS laboratories every year. Endorse-
ment of cystatin C testing in international guidance [38]
together with the increasing availability of cystatin C as-
says on large, automated laboratory test platforms will
increase the pressure on NHS laboratories to introduce
this test, which is significantly more expensive than cre-
atinine testing. Whilst introduction of routine GFR esti-
mations is generally deemed to have brought significant
health advantages [64] there is also concern that non-
diseased individuals may be identified who may undergo
inappropriate investigation and surveillance [8]. Further,
the ability of tests to identify which individuals with
CKD will have high risk (i.e. progressive or mortal) dis-
ease is seen as a crucial issue. A significant problem has
been the ability of GFR-estimating equations to identify
progression of kidney disease given the biological vari-
ability of its main determinant (serum creatinine). There
have been no prospective studies of the ability of GFR
estimating equations to monitor progression and no stud-
ies at all of GFR estimating equations incorporating cysta-
tin C; there have been no validations of GFR estimating
equations in British ethnic minority populations. The pro-
posed study will address these important issues.
We have chosen plasma iohexol clearance as the refer-
ence measure of GFR for our study because it is equiva-
lent to inulin clearance, is widely used in clinical and
research practice, is non-radioisotopic, can be measured
accurately and precisely, and is cheap [13,65,66]. The CKD-
EPI and MDRD equations will be studied because they are
anchored to both creatinine and cystatin C reference meth-
odology and therefore likely to generate data that will be
valid in perpetuity. Other more recently published equa-
tions will also be evaluated (e.g. Berlin Initiative Study
equations [28]). The study population will be a large cohort
of people with stage 3 CKD including subjects of African-
Caribbean and Asian ethnicity as well as subjects with
diabetes and proteinuria. A sub-study will model disease
progression in a smaller cohort. This will build on the
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design with regular reference GFR measurements: the
impact of medication on disease progression will be es-
timated and included in the model. The model will be
used to define optimal sampling times for high and low
risk participants, and other significant subgroups de-
fined by the model. We will also use a classical study de-
sign to establish the biological variability of both reference
and estimated GFR: this information will be used as one
of the handles in defining progression and assessing the
ability of GFR-estimating equations to detect it.
Study status
The eGFR-C study commenced on 1st August 2013 and
will open to recruitment in February 2014. The study
co-sponsors are East Kent Hospitals University NHS
Foundation Trust and University of Birmingham (Ref:
RG_13-176). eGFR-C is being co-ordinated by the Uni-
versity of Birmingham Clinical Trials Unit. eGFR-C first
received ethical approval from the South-East Coast-
Surrey Research Ethics Committee of the National Re-
search Ethics Service on 9th October 2013 (reference
number 13/LO/1349). The NIHR CRN portfolio study
number is 15268 and the study is registered as ISRCTN
42955626. Further information may be found on
the study website http://www.birmingham.ac.uk/egfr-c
(accessed 18th December 2013).
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